Immunohistochemical and clinicopathologic features of estrogen receptor-negative, progesterone receptor-positive, HER-2 negative breast carcinomas-Reference-Cited by-同舟云学术

Immunohistochemical and clinicopathologic features of estrogen receptor-negative, progesterone receptor-positive, HER-2 negative breast carcinomas

Published:2021-02 Issue:2 Volume:67 Page:265-270
ISSN:1806-9282
Container-title:Revista da Associação Médica Brasileira
language:
Short-container-title:Rev. Assoc. Med. Bras.

Author:

Nardi Rosana Pellin De¹^ORCID,Uchoa Diego¹^ORCID,Remonatto Gabriela¹^ORCID,Biazus Jorge Villanova²^ORCID,Damin Andrea Pires²^ORCID

Affiliation:

1. Universidade Federal do Rio Grande do Sul, Brazil

2. Universidade Federal do Rio Grande do Sul, Brazil; Universidade Federal do Rio Grande do Sul, Brazil

Publisher

FapUNIFESP (SciELO)

Subject

General Medicine

Link

http://www.scielo.br/pdf/ramb/v67n2/1806-9282-ramb-67-02-0265.pdf

Reference25 articles.

1. Molecular portraits of human breast tumours;Perou CM;Nature,2000

2. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study;Carey LA;JAMA,2006

3. Repeated observation of breast tumor subtypes in independent gene expression data sets;Sorlie T;Proc Natl Acad Sci U S A,2003

4. Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer;Li Y;JAMA Netw Open,2020

5. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy;Cui X;J Clin Oncol,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction model of the unbalanced expression of hormone receptor in HER2-negative Breast Cancer;2023-12-16

2. Synergistic effects of ozone with doxorubicin on the proliferation, apoptosis and metastatic profile of luminal-B type human breast cancer cell line;Tissue and Cell;2023-12

3. Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER−PR+HER2−) breast cancer;Translational Breast Cancer Research;2023-01